Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Neutral Phosphate for Calcium Oxalate Kidney Stones
NCT07903961Phase 1Not yet recruiting
- Sponsor
- University of Chicago
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of potassium phosphate + sodium phosphate in nephrolithiasis and hypophosphatemia, sponsored by University of Chicago. Primary endpoint: Change in Urine Calcium at 2 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
potassium phosphate + sodium phosphate
03
Conditions
nephrolithiasishypophosphatemia
Beyond the preview
Go deeper on NCT07903961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07903961.